Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Preimplantation genetic testing (PGT-M) awareness in BRCA-positive individuals in Türkiye: a dual physician-patient survey.

Scientific reports·2026
Same author

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

Cancers·2026
Same author

Real-World 30-Day Mortality After the Last Dose of Immune Checkpoint Inhibitors: A Multicenter Retrospective Cohort Study in Turkey.

Current oncology (Toronto, Ont.)·2026
Same author

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Current oncology (Toronto, Ont.)·2026
Same author

Regarding: Nachira D, Calabrese G, Bertolaccini L, et al. Oncological outcomes and prognostic factors of pulmonary metastasectomy in pancreatic cancer : Updates in Surgery, 2026, https://doi.org/10.1007/s13304-026-02605-x.

Updates in surgery·2026
Same author

Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study.

JCO oncology practice·2026

相关实验视频

Updated: May 5, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K

对于L型肉 Sarcoma的trabectedin:一个回顾性的多中心研究.

Sercan Ön1, Barış Köksal2, Zafer Arık2

  • 1Department of Medical Oncology, Tepecik Training and Research Hospital, 35180 Izmir, Türkiye.

Current oncology (Toronto, Ont.)
|November 26, 2024
PubMed
概括
此摘要是机器生成的。

特拉贝克泰丁在转移性L型瘤中是有效的,这种瘤是在安赛克林后出现的. 局部治疗和客观反应与更好的结果相关,而剂量减少不会使这些罕见癌症的存活率恶化.

关键词:
毒性毒性毒性毒性毒性毒性毒性毒性毒性毒性毒埃克泰纳斯基丁 743 种莱奥米奥萨科马斯 (leiomyosarcomas) 是一种癌症.脂质沙尔科马 (liposarcomas) 是一种有针对性的放射治疗.在trabectedin中进行了追踪

更多相关视频

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.6K

相关实验视频

Last Updated: May 5, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.6K

科学领域:

  • 医学瘤学 医学瘤学
  • 肉瘤研究研究 肉瘤研究
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 转移性L型肉瘤 (脂肉瘤,乳腺肉瘤) 是罕见的,预后不佳.
  • 特拉贝克丁是继安赛克林治疗后的一种已知治疗选择.

研究的目的:

  • 评估特拉贝克丁在转移性L型肉瘤中的实际有效性和安全性.
  • 确定影响治疗结果的预后因素.

主要方法:

  • 对98名用trabectedin.in治疗的患者进行了回顾性多中心研究.
  • 评估客观反应率 (ORR),疾病控制率 (DCR),治疗失败的时间 (TTF) 和整体存活率 (OS).
  • 考克斯回归分析用于预后因素识别.

主要成果:

  • ORR为16%,DCR为42%,TTF中位数为3个月,OS中位数为10个月.
  • 局部治疗和客观反应与更长的TTF有关.
  • 客观反应是OS的积极预后因素;肝转移表明预后不佳.

结论:

  • 特拉贝克丁是一种可行的治疗方法,用于L型肉 Sarcoma post-anthracyclines.
  • 降低剂量并没有对存活率产生负面影响.
  • 将特拉贝克丁与局部疗法结合使用可能会提高疗效.